Entera Bio Ltd.

ENTX Healthcare Biotechnology

Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.48 0.17 −6.42%
Market cap
$460.7M
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
n/a
Altman Z
6.22
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.98 7.93 6.94 10.83
Net Debt/EBITDA
4.05 3.38 4.90 5.11
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.07) (0.06) (0.04) (0.05)
Book value per Share
0.14 0.22 0.28 0.32
Free Cash Flow
(3.47) (3.09) (1.86) (2.54)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates